MARKET

CBAY

CBAY

Cymabay Therapeu
NASDAQ
3.940
+0.010
+0.26%
Opening 14:36 12/08 EST
OPEN
3.960
PREV CLOSE
3.930
HIGH
3.985
LOW
3.830
VOLUME
107.68K
TURNOVER
239.34K
52 WEEK HIGH
4.300
52 WEEK LOW
1.670
MARKET CAP
333.68M
P/E (TTM)
-3.1586
1D
5D
1M
3M
1Y
5Y
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) may have lost US$34m in value but insiders who invested last year have seen gains of around US$72k to date
Insiders who bought CymaBay Therapeutics, Inc. ( NASDAQ:CBAY ) stock lover the last 12 months are probably not as...
Simply Wall St. · 11/23 15:40
Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?
Here is how Gilead Sciences (GILD) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.
Zacks · 11/17 14:40
--Oppenheimer Adjusts Cymabay Therapeutics Price Target to $10 From $12, Maintains Outperform Rating
--Oppenheimer Adjusts Cymabay Therapeutics Price Target to $10 From $12, Maintains Outperform Rating
MT Newswires · 11/16 08:26
BRIEF-CymaBay Reports Third Quarter And Nine Months Ended Sept 30 Financial Results
Reuters · 11/14 21:43
CymaBay Therapeutics GAAP EPS of -$0.28 beats by $0.02
Seekingalpha · 11/14 21:17
CymaBay Therapeutics Q3 EPS $(0.28) Beats $(0.30) Estimate
Benzinga · 11/14 21:14
Earnings Reaction History: CymaBay Therapeutics Inc, 50.0% Follow-Through Indicator, 17.2% Sensitive
Earnings Reaction History: CymaBay Therapeutics Inc, 50.0% Follow-Through Indicator, 17.2% Sensitive
MT Newswires · 11/14 12:19
Notable earnings after Monday's close
Seekingalpha · 11/13 22:35
More
About CBAY
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and providing access to therapies for patients with liver and other chronic diseases. The Company's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation, and fibrosis. It is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation. Its other product candidate, MBX-2982, targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.

Webull offers kinds of CymaBay Therapeutics Inc stock information, including NASDAQ:CBAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBAY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CBAY stock methods without spending real money on the virtual paper trading platform.